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Abstract #2
Background
• Existing antiretroviral therapy (ART) is characterised by life-long daily 
administration
• Long-acting (LA) strategies could limit the problems associated with pill 
fatigue and sub-optimal adherence 
• Antiretrovirals are currently developed for intramuscular injectable LA 
formulations 
• Transdermal delivery through microneedle array patches represent an 
alternative strategy for LA administration 
Microneedle array patches (MAPs)
• Consist of micron-sized needle arrays of varying sizes capable of disrupting 
stratum corneum
• Capable of local and systemic delivery, blood-free with painless application
• Provide patient friendly, low cost and minimally invasive route for drug 
delivery 
• Deliver intact nanoformulations that form a depot in the upper skin layers
• Drug release from this nanoparticulate formulation is the rate limiting step 
to regulate pharmacokinetics






• Mathematical description of absorption, distribution, metabolism and elimination 
processes defining pharmacokinetics 






• Design a transdermal PBPK model to simulate pharmacokinetics of a model drug resulting 
from administration through microneedles
• Predict pharmacokinetics of a model drug across a range of dose and release rate in 























P – permeability , PC – partition coefficient






Route and dose Cmax AUC Cmin Cmax AUC Cmin Cmax AUC Cmin
Intramuscular
(5 mg/kg, single injection)1
71 3840 - 55.9 ± 6.43 5.67 ± 1.25 - -21.3 47.6 -
Intramuscular
(20 mg/kg, single injection)1
158 15300 - 222 ± 25.5 22.4 ± 4.64 - 40.5 46.3 -
Transdermal
†(120 mg, microneedle patch)2
416 - 26.5 481 ± 42.9 286 ± 28.1 38.7 ± 4.45 24.5 - 46.0
Values are represented as arithmetic mean ± standard deviation where ever applicable, AUC – area under the concentration-time curve, Cmax – maximum
plasma concentration, Ctrough – trough plasma concentration; Cmax and Ctrough are expressed as ng/ml and AUC is expressed as µg × h/ml;* PBPK model is
assumed to be qualified if % difference is less than 50, † Only 57.45 % of the total administered drug was assumed to be delivered using microneedle3
Rat in vivo
1 van ′t Klooster G, Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation.  2010 
2 Darin Zehrung, Development of microarray patches for transdermal and vaginal delivery of long-acting HIV pre-exposure prophylaxis, 2016 
3 Garland MJ et al. Influence of skin model on in vitro performance of drug-loaded soluble microneedle arrays. International Journal of Pharmaceutics. 2012;434(1):80-9.



















Transdermal release predictions – plasma concentrations
720 mg  4-weekly dose vs. various release rates (h-1)
• Ctrough increases up to a certain release rate and then decreases
• Ctrough was proportional to the increase in administered transdermal dose
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Ctrough at the end of two 4-weekly doses
Target Ctrough25 mg PO CtroughTarget Ctrough
Transdermal predictions – Ctrough vs. penetration depth, pore radius
Pharmacokinetic summary at various needle lengths
• Constant dose – 720 mg, constant release rate – 0.0015 h-1
• No significant difference observed in Ctrough (P > 0.05)
Constant pore size – 224 µm1
Pharmacokinetic summary at various pore radii
Constant needle length – 429.66 µm1
1 Garland MJ et al. Influence of skin model on in vitro performance of drug-loaded soluble microneedle arrays. International Journal of Pharmaceutics. 2012;434(1):80-9.
Limitations
• Immune response at the site of administration could alter the release rate 
• Evaluation of long-term drug and excipients stability at the administration 
site is pivotal
• Modelled formulation release rate cannot be directly extrapolated to release 
rate in vivo
• Further qualification against transdermal PK from human data would improve 
the confidence of the PBPK model
Summary
• Transdermal delivery represents an attractive, minimally invasive and effective 
route for long-acting ART administration
• Design of the transdermal PBPK model was successfully qualified against observed 
data in rats
• Dose and release rate was optimised for a model drug for a monthly transdermal 
MAPs
• Transdermal PBPK model is a platform to rationalise selection of drug candidates 
for LA therapy using MAPs
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